Nutex Health Inc. — Q2 2022 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2022; filed August 22, 2022. Nutex is a physician-led healthcare services company operating 21 hospital facilities in eight states and a population health management business. The April 1, 2022 merger with Clinigence was accounted for as a reverse acquisition; pre-merger comparative periods reflect Nutex Health Holdco, while Clinigence is included only from April 1, 2022. Comparisons therefore are not fully like-for-like.
Key financial results
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | 2022: $58.0 million; 2021: $62.8 million | 2022: $137.2 million; 2021: $150.2 million |
| Operating income (loss) | 2022: $(1.4) million; 2021: $27.6 million | 2022: $27.9 million; 2021: $80.3 million |
| Net income (loss) attributable to Nutex | 2022: $(19.4) million; 2021: $27.1 million | 2022: $2.1 million; 2021: $64.8 million |
| Adjusted EBITDA (non-GAAP) | 2022: $9.4 million; 2021: $30.0 million | 2022: $33.6 million; 2021: $69.7 million |
Q2 reported revenue declined 7.6%; hospital division revenue fell 18% to $51.6 million. Population health management contributed $6.4 million from the post-merger period. The filing reports Q2 gross profit of $5.0 million, approximately 8.6% of revenue, versus $29.1 million, approximately 46.4%, in Q2 2021. Hospital visits rose 17% to 33,175, but lower collections and case severity, higher labor and contractor costs, and start-up costs pressured results. Five newer facilities were not yet at break-even; management generally expects new facilities to reach break-even within 12–15 months.
For the six-month period, hospital revenue declined 13% to $130.7 million and hospital segment operating income declined 53% to $39.6 million. Hospital visits increased 14% to 84,931. The population health management division reported a $0.3 million operating loss for the period since it began contributing after the merger.
Cash flow, balance sheet and capital
- Cash and equivalents were $47.6 million at June 30, 2022, up from $36.1 million at December 31, 2021. Six-month operating cash flow was $53.4 million, investing cash flow $(6.3) million, and financing cash flow $(35.6) million.
- Capital expenditures were $16.6 million. Financing cash outflows included $47.8 million of owner and noncontrolling-interest distributions.
- Total assets were $871.8 million and total equity $566.4 million. Current assets of $149.0 million exceeded current liabilities of $56.5 million; accounts receivable was $94.7 million.
- Reported debt was $26.7 million before debt issuance costs and classification of current amounts; $16.3 million was reflected as long-term debt. Debt was $89.4 million at year-end 2021, with the decrease largely related to deconsolidation of real estate entities. Financing lease liabilities were $196.1 million and operating lease liabilities $24.4 million at June 30; lease obligations are distinct from the debt figures above.
- A revolving credit facility was not in compliance with its debt-service-coverage covenant at June 30; its $2.6 million balance was classified as current. Remaining availability under lines of credit was $1.7 million.
- Merger accounting added approximately $424.2 million of goodwill and $21.7 million of identified intangible assets. The company also deconsolidated 17 real estate entities in Q2, with no reported gain or loss.
Material changes, outlook and risks
- Management attributed lower hospital revenue and collections primarily to the No Surprises Act (NSA), effective January 1, 2022. The company reported significant declines in emergency-claim collections and limited success obtaining payments above the qualifying payment amount through independent dispute resolution. The outcome of rulemaking and legal challenges remained uncertain.
- Q2 net loss included $19.7 million of income tax expense, including a net $18.4 million of one-time, noncash tax items related principally to Nutex’s change in tax status after the merger and release of Clinigence’s deferred-tax valuation allowance. Q2 also included $3.9 million of acquisition costs. Management expects interest expense to decline following real estate deconsolidations and conversion of the remaining merger-related notes.
- Management stated that existing cash, cash equivalents and restricted cash should fund operating and capital needs for at least the next twelve months, based on its current operating plan and assumptions. It also plans to expand through new hospitals, IPAs and acquisitions, and was seeking larger financing commitments; availability and terms were uncertain. No specific revenue or earnings guidance was provided.
- COVID-19-related labor, supply-chain, construction and inflation pressures, delayed billing and collections, reimbursement uncertainty, new-facility ramp costs, and growth execution may affect results. The company also cited risks from healthcare regulation, payor audits, physician recruitment, related-party arrangements and the financial risks of capitated care.
- Disclosure controls were deemed ineffective at June 30, 2022 because of previously identified material weaknesses involving revenue estimates, lease accounting and the accounting close process. Remediation was ongoing and had not been validated as effective.
- The filing reports routine legal matters but no litigation material to ongoing operations; management did not expect routine claims to have a material adverse effect. The company disclosed no material off-balance-sheet arrangements.
Investor verification priorities
- Track NSA-related collections, IDR outcomes, accounts-receivable aging and any further changes to revenue-estimation assumptions.
- Verify covenant compliance, credit availability, debt maturities and the full cash burden of financing and operating leases.
- Assess hospital-level margins and whether newer facilities reach break-even on the stated 12–15-month timeline; separate mature-facility performance from start-up costs.
- Monitor remediation and independent validation of the material weaknesses in financial reporting controls.
- Review merger-related dilution: shares issued, remaining options and warrants, potential additional stock issuances tied to hospital performance, and lock-up expirations and resale registrations.
- Evaluate the effect of related-party leases and management agreements, including arrangements involving the CEO and affiliated entities, and the risks of consolidating variable-interest entities without ownership.